Evaluating the Efficacy of Neoadjuvant Endocrine Therapy in HER2-Low Versus HER2-Negative Breast Cancer
{{output}}
HER2-low breast cancer has emerged as a distinct biological subtype with implications for treatment response. However, its impact on response to neoadjuvant endocrine therapy (NET) in hormone receptor-positive (HR+) breast cancer remains unclear. The objective... ...
